US5066789A
(en)
*
|
1988-09-30 |
1991-11-19 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having Schiff base linkages
|
WO1990003401A1
(en)
*
|
1988-09-30 |
1990-04-05 |
Neorx Corporation |
Targeting substance-diagnostic/therapeutic agent conjugates having schiff base linkages
|
US5576288A
(en)
*
|
1989-04-27 |
1996-11-19 |
The Salk Institute For Biological Studies |
Fibroblast growth factor conjugates
|
US5527527A
(en)
*
|
1989-09-07 |
1996-06-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US5977307A
(en)
*
|
1989-09-07 |
1999-11-02 |
Alkermes, Inc. |
Transferrin receptor specific ligand-neuropharmaceutical agent fusion proteins
|
US5182107A
(en)
*
|
1989-09-07 |
1993-01-26 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US5154924A
(en)
*
|
1989-09-07 |
1992-10-13 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical agent conjugates
|
US6329508B1
(en)
|
1989-09-07 |
2001-12-11 |
Alkermes, Inc. |
Transferrin receptor reactive chimeric antibodies
|
US5672683A
(en)
*
|
1989-09-07 |
1997-09-30 |
Alkermes, Inc. |
Transferrin neuropharmaceutical agent fusion protein
|
US6610299B1
(en)
|
1989-10-19 |
2003-08-26 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US7241595B2
(en)
*
|
1989-10-20 |
2007-07-10 |
Sanofi-Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US6475486B1
(en)
|
1990-10-18 |
2002-11-05 |
Aventis Pharma Deutschland Gmbh |
Glycosyl-etoposide prodrugs, a process for preparation thereof and the use thereof in combination with functionalized tumor-specific enzyme conjugates
|
US5137877B1
(en)
*
|
1990-05-14 |
1996-01-30 |
Bristol Myers Squibb Co |
Bifunctional linking compounds conjugates and methods for their production
|
GB9017024D0
(en)
*
|
1990-08-03 |
1990-09-19 |
Erba Carlo Spa |
New linker for bioactive agents
|
CA2048089A1
(en)
*
|
1990-09-17 |
1992-03-18 |
Wolfgang A. Wrasidlo |
Chemical conjugation of morpholino anthracyclines to antibodies
|
US5776458A
(en)
*
|
1990-12-05 |
1998-07-07 |
Pharmacia & Upjohn S.P.A. |
Anthracycline-conjugates
|
GB9026491D0
(en)
*
|
1990-12-05 |
1991-01-23 |
Erba Carlo Spa |
Anthracycline-conjugates
|
US5272253A
(en)
*
|
1991-07-01 |
1993-12-21 |
Eli Lilly And Company |
Cluster conjugates of drugs with antibodies
|
US5622929A
(en)
*
|
1992-01-23 |
1997-04-22 |
Bristol-Myers Squibb Company |
Thioether conjugates
|
US5505931A
(en)
*
|
1993-03-04 |
1996-04-09 |
The Dow Chemical Company |
Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents
|
GR1001459B
(el)
*
|
1992-10-08 |
1993-12-30 |
Lilly Co Eli |
Σύμπλεγμα συζυγών φαρμάκων με αντισώματα.
|
DE4236237A1
(de)
*
|
1992-10-27 |
1994-04-28 |
Behringwerke Ag |
Prodrugs, ihre Herstellung und Verwendung als Arzneimittel
|
US5556623A
(en)
*
|
1993-03-30 |
1996-09-17 |
Eli Lilly And Company |
Antibody-drug conjugates
|
US6551618B2
(en)
|
1994-03-15 |
2003-04-22 |
University Of Birmingham |
Compositions and methods for delivery of agents for neuronal regeneration and survival
|
DE4435087A1
(de)
*
|
1994-09-30 |
1996-04-04 |
Deutsches Krebsforsch |
Konjugat zur Behandlung von Infektions-, Autoimmun- und Hauterkrankungen
|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
US20030119724A1
(en)
*
|
1995-11-22 |
2003-06-26 |
Ts`O Paul O.P. |
Ligands to enhance cellular uptake of biomolecules
|
US5843903A
(en)
*
|
1995-11-27 |
1998-12-01 |
The Administrators Of The Tulane Educational Fund |
Targeted cytotoxic anthracycline analogs
|
JP2000503639A
(ja)
*
|
1995-12-22 |
2000-03-28 |
ブリストル―マイヤーズ スクイブ カンパニー |
分枝ヒドラゾンのリンカー類
|
US6759509B1
(en)
|
1996-11-05 |
2004-07-06 |
Bristol-Myers Squibb Company |
Branched peptide linkers
|
EP0941120A4
(de)
*
|
1996-11-05 |
2004-08-18 |
Bristol Myers Squibb Co |
Verzweigte peptidlinker
|
CA2248592A1
(en)
|
1998-08-31 |
2000-02-29 |
Christopher D. Batich |
Microspheres for use in the treatment of cancer
|
GB9917012D0
(en)
*
|
1999-07-20 |
1999-09-22 |
Pharmacia & Upjohn Spa |
Combined preparations comprising antitumor agents
|
US20060014684A1
(en)
*
|
2000-03-03 |
2006-01-19 |
University Technologies International Inc. |
Novel uses of EGF
|
US6586207B2
(en)
|
2000-05-26 |
2003-07-01 |
California Institute Of Technology |
Overexpression of aminoacyl-tRNA synthetases for efficient production of engineered proteins containing amino acid analogues
|
WO2001095943A2
(en)
*
|
2000-06-14 |
2001-12-20 |
Medarex, Inc. |
Prodrug compounds with an oligopeptide having an isoleucine residue
|
US6624317B1
(en)
|
2000-09-25 |
2003-09-23 |
The University Of North Carolina At Chapel Hill |
Taxoid conjugates as antimitotic and antitumor agents
|
AU2002217980A1
(en)
|
2000-12-01 |
2002-06-11 |
Cell Works Inc. |
Conjugates of glycosylated/galactosylated peptide
|
WO2002049672A2
(en)
*
|
2000-12-21 |
2002-06-27 |
Mcgill University |
Conjugates of antibodies and anticancer drugs
|
US7445802B2
(en)
*
|
2000-12-26 |
2008-11-04 |
Yeda Research And Development Co. Ltd |
Site-specific in situ generation of allicin using a targeted alliinase delivery system for the treatment of cancers, tumors, infectious diseases and other allicin-sensitive diseases
|
US7754208B2
(en)
|
2001-01-17 |
2010-07-13 |
Trubion Pharmaceuticals, Inc. |
Binding domain-immunoglobulin fusion proteins
|
US7829084B2
(en)
*
|
2001-01-17 |
2010-11-09 |
Trubion Pharmaceuticals, Inc. |
Binding constructs and methods for use thereof
|
US20100056762A1
(en)
|
2001-05-11 |
2010-03-04 |
Old Lloyd J |
Specific binding proteins and uses thereof
|
ES2552281T3
(es)
|
2001-05-11 |
2015-11-26 |
Ludwig Institute For Cancer Research Ltd. |
Proteínas de unión específica y usos de las mismas
|
CA2447335C
(en)
*
|
2001-05-15 |
2011-01-04 |
Faulk Pharmaceuticals, Inc. |
Targeted delivery of drugs for the treatment of viral infections
|
WO2003035102A1
(en)
*
|
2001-10-26 |
2003-05-01 |
University Technologies International, Inc. |
Use of egf to inhibit pathogenic infections of the urogenital tract
|
RU2196604C1
(ru)
*
|
2001-12-21 |
2003-01-20 |
Северин Евгений Сергеевич |
Полипептид, являющийся аналогом рецепторсвязывающего фрагмента эпидермального фактора роста с 21-й по 31-ю аминокислоту, его конъюгат с доксорубицином и фармацевтическая композиция на его основе
|
US9770517B2
(en)
|
2002-03-01 |
2017-09-26 |
Immunomedics, Inc. |
Anti-Trop-2 antibody-drug conjugates and uses thereof
|
EP1545613B9
(de)
|
2002-07-31 |
2012-01-25 |
Seattle Genetics, Inc. |
Auristatin-konjugate und ihre verwendung zur behandlung von krebs, einer autoimmunkranheit oder einer infektionskrankheit
|
WO2004054622A1
(en)
|
2002-12-13 |
2004-07-01 |
Immunomedics, Inc. |
Immunoconjugates with an intracellularly-cleavable linkage
|
JP5356648B2
(ja)
|
2003-02-20 |
2013-12-04 |
シアトル ジェネティックス, インコーポレイテッド |
抗cd70抗体−医薬結合体、ならびに癌および免疫障害の処置のためのそれらの使用
|
US20040171175A1
(en)
*
|
2003-02-28 |
2004-09-02 |
Swanson Basil I. |
Process for conjugating biomolecules to hydrophobic membrane-incorporated molecules
|
US20040219103A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods useful for the diagnosis, imaging and treatment of tumors
|
US20040219101A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for treatment of tumors
|
US20040220390A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040220085A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for nucleic acid delivery
|
US20040220084A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for nucleic acid delivery
|
US20040219099A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Method for the treatment of tumors
|
US20040219102A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Compositions for drug delivery
|
US20040219100A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the treatment of tumors
|
US20040219104A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for treatment of tumors
|
US20040219097A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Composition useful for the diagnosis, imaging and treatment of tumors
|
US20040220121A1
(en)
*
|
2003-05-02 |
2004-11-04 |
Jasbir Sandhu |
Methods for drug delivery
|
EP1680073B1
(de)
*
|
2003-10-21 |
2013-01-02 |
IGF Oncology, LLC |
Verbindungen und verfahren zur behandlung von krebs
|
US9011880B2
(en)
*
|
2003-10-21 |
2015-04-21 |
Igf Oncology, Llc |
Compounds and methods for treating cancer
|
KR101520209B1
(ko)
|
2003-11-06 |
2015-05-13 |
시애틀 지네틱스, 인크. |
리간드에 접합될 수 있는 모노메틸발린 화합물
|
WO2005072292A2
(en)
*
|
2004-01-24 |
2005-08-11 |
Hugh Mctavish |
Methods for enhancing radiation therapy
|
US20050175619A1
(en)
*
|
2004-02-05 |
2005-08-11 |
Robert Duffy |
Methods of producing antibody conjugates
|
US20050287639A1
(en)
|
2004-05-17 |
2005-12-29 |
California Institute Of Technology |
Methods of incorporating amino acid analogs into proteins
|
EP1812082B1
(de)
*
|
2004-10-21 |
2013-08-14 |
IGF Oncology, LLC |
An IGF-1-Rezeptorliganden gekoppelte Toxine und Radionuklide zur Krebsbehandlung
|
CA2589374C
(en)
|
2004-11-30 |
2016-05-03 |
Curagen Corporation |
Antibodies directed to gpnmb and uses thereof
|
US10058621B2
(en)
|
2015-06-25 |
2018-08-28 |
Immunomedics, Inc. |
Combination therapy with anti-HLA-DR antibodies and kinase inhibitors in hematopoietic cancers
|
US9707302B2
(en)
|
2013-07-23 |
2017-07-18 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
WO2006104970A1
(en)
|
2005-03-30 |
2006-10-05 |
Saladax Biomedical Inc. |
Doxorubicin immunoassay
|
DK1912675T3
(en)
|
2005-07-25 |
2014-03-24 |
Emergent Product Dev Seattle |
B-cell reduction using specific and cd37-cd20-specific binding molecules
|
US8052971B2
(en)
*
|
2005-11-21 |
2011-11-08 |
MG Biologics |
Oral use of specific antibodies for intestinal health
|
WO2008069824A2
(en)
*
|
2006-02-27 |
2008-06-12 |
The Board Of Trustees Of The Leland Stanford Junior University |
Compositions and methods for transport of molecules with enhanced release properties across biological barriers
|
EP2001358B1
(de)
*
|
2006-03-27 |
2016-07-13 |
University Of Maryland, Baltimore |
Glycoprotein-synthese und -neumodellierung durch enzymatische transglycosylierung
|
US8455622B2
(en)
|
2006-12-01 |
2013-06-04 |
Seattle Genetics, Inc. |
Variant target binding agents and uses thereof
|
US9090693B2
(en)
|
2007-01-25 |
2015-07-28 |
Dana-Farber Cancer Institute |
Use of anti-EGFR antibodies in treatment of EGFR mutant mediated disease
|
MX2009009782A
(es)
|
2007-03-15 |
2010-09-10 |
Ludwig Inst Cancer Res |
Metodo de tratamiento que utiliza anticuerpos egfr e inhibidores de src y formulaciones relacionadas.
|
JP5469600B2
(ja)
|
2007-07-16 |
2014-04-16 |
ジェネンテック, インコーポレイテッド |
抗CD79b抗体及びイムノコンジュゲートとその使用方法
|
TW200918089A
(en)
|
2007-07-16 |
2009-05-01 |
Genentech Inc |
Humanized anti-CD79b antibodies and immunoconjugates and methods of use
|
WO2009023265A1
(en)
|
2007-08-14 |
2009-02-19 |
Ludwig Institute For Cancer Research |
Monoclonal antibody 175 targeting the egf receptor and derivatives and uses thereof
|
WO2009046407A2
(en)
|
2007-10-04 |
2009-04-09 |
Zymogenetics, Inc. |
B7 FAMILY MEMBER zB7H6 AND RELATED COMPOSITIONS AND METHODS
|
AU2009205995B2
(en)
|
2008-01-18 |
2014-04-03 |
Medimmune, Llc |
Cysteine engineered antibodies for site-specific conjugation
|
SI2657253T1
(sl)
|
2008-01-31 |
2017-10-30 |
Genentech, Inc. |
Protitelesa proti CD79b in imunokonjugati in postopki za uporabo
|
ES2547552T3
(es)
|
2008-02-01 |
2015-10-07 |
Genentech, Inc. |
Metabolito de nemorrubicina y reactivos análogos, conjugados anticuerpo-fármaco y métodos
|
AU2009270988A1
(en)
|
2008-07-15 |
2010-01-21 |
Genentech, Inc. |
Anthracycline derivative conjugates, process for their preparation and their use as antitumor compounds
|
WO2010014236A2
(en)
*
|
2008-07-30 |
2010-02-04 |
The University Of North Carolina At Chapel Hill |
Acylhydrazone-based cleavable linkers
|
WO2011005481A1
(en)
|
2009-06-22 |
2011-01-13 |
Medimmune, Llc |
ENGINEERED Fc REGIONS FOR SITE-SPECIFIC CONJUGATION
|
US9493578B2
(en)
|
2009-09-02 |
2016-11-15 |
Xencor, Inc. |
Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
|
IN2012DN02604A
(de)
|
2009-10-23 |
2015-09-04 |
Millennium Pharm Inc |
|
MX2012006443A
(es)
|
2009-12-09 |
2012-06-28 |
Inst Nat Sante Rech Med |
Anticuerpos monoclonales que se enlazan a b7h6 y usos de los mismos.
|
KR101510413B1
(ko)
|
2010-02-08 |
2015-04-08 |
어젠시스 인코포레이티드 |
161p2f10b 단백질에 결합하는 항체 약물 컨쥬게이트
|
CN102971012B
(zh)
*
|
2010-03-12 |
2016-05-04 |
伊缪诺金公司 |
Cd37结合分子及其免疫缀合物
|
JP5953303B2
(ja)
|
2010-07-29 |
2016-07-20 |
ゼンコア インコーポレイテッド |
改変された等電点を有する抗体
|
PT2621526T
(pt)
|
2010-09-29 |
2018-08-02 |
Seattle Genetics Inc |
Conjugados de anticorpo com fármaco (adc) que se ligam a proteínas 191pad12
|
US9228023B2
(en)
|
2010-10-01 |
2016-01-05 |
Oxford Biotherapeutics Ltd. |
Anti-ROR1 antibodies and methods of use for treatment of cancer
|
RU2563638C2
(ru)
|
2010-12-02 |
2015-09-20 |
НЕРВИАНО МЕДИКАЛ САЙЕНСИЗ С.р.л. |
Способ получения производных морфолинилантрациклина
|
SG190938A1
(en)
|
2010-12-06 |
2013-07-31 |
Seattle Genetics Inc |
Humanized antibodies to liv-1 and use of same to treat cancer
|
JOP20210044A1
(ar)
|
2010-12-30 |
2017-06-16 |
Takeda Pharmaceuticals Co |
الأجسام المضادة لـ cd38
|
CN103596590A
(zh)
|
2011-04-01 |
2014-02-19 |
伊缪诺金公司 |
Cd37结合分子及其免疫缀合物
|
PT3415531T
(pt)
|
2011-05-27 |
2023-09-12 |
Glaxo Group Ltd |
Proteínas de ligação a bcma (cd269/tnfrsf17
|
WO2013022855A1
(en)
|
2011-08-05 |
2013-02-14 |
Xencor, Inc. |
Antibodies with modified isoelectric points and immunofiltering
|
US20130058947A1
(en)
|
2011-09-02 |
2013-03-07 |
Stem Centrx, Inc |
Novel Modulators and Methods of Use
|
JP6310394B2
(ja)
|
2011-10-10 |
2018-04-11 |
ゼンコア インコーポレイテッド |
抗体を精製する方法
|
US10851178B2
(en)
|
2011-10-10 |
2020-12-01 |
Xencor, Inc. |
Heterodimeric human IgG1 polypeptides with isoelectric point modifications
|
WO2013063702A1
(en)
|
2011-11-04 |
2013-05-10 |
Zymeworks Inc. |
Stable heterodimeric antibody design with mutations in the fc domain
|
EP2592103A1
(de)
|
2011-11-08 |
2013-05-15 |
Adriacell S.p.A. |
Polymeraldehydderivate
|
JP2015502397A
(ja)
|
2011-12-23 |
2015-01-22 |
ファイザー・インク |
部位特異的コンジュゲーションのための操作された抗体定常領域、ならびにそのための方法および使用
|
WO2013109994A1
(en)
|
2012-01-20 |
2013-07-25 |
Sea Lane Biotechnologies, Llc |
Surrobody cojugates
|
DK2817338T3
(en)
|
2012-02-24 |
2017-10-23 |
Abbvie Stemcentrx Llc |
DLL3 modulators and methods of use
|
AR090549A1
(es)
|
2012-03-30 |
2014-11-19 |
Genentech Inc |
Anticuerpos anti-lgr5 e inmunoconjugados
|
US9816066B2
(en)
|
2012-04-24 |
2017-11-14 |
The Regents Of The University Of California |
Method for delivery of small molecules and proteins across the cell wall of algae using molecular transporters
|
RU2014148162A
(ru)
|
2012-05-01 |
2016-06-20 |
Дженентек, Инк. |
Анти-pmel17 антитела и их иммуноконъюгаты
|
KR102433686B1
(ko)
|
2012-05-15 |
2022-08-19 |
씨젠 인크. |
자가-안정화 링커 접합체
|
SG11201500096YA
(en)
|
2012-07-09 |
2015-02-27 |
Genentech Inc |
Immunoconjugates comprising anti - cd79b antibodies
|
CA2874904A1
(en)
|
2012-07-09 |
2014-01-16 |
Genentech, Inc. |
Immunoconjugates comprising anti-cd22 antibodies
|
CN112587658A
(zh)
|
2012-07-18 |
2021-04-02 |
博笛生物科技有限公司 |
癌症的靶向免疫治疗
|
US9382329B2
(en)
|
2012-08-14 |
2016-07-05 |
Ibc Pharmaceuticals, Inc. |
Disease therapy by inducing immune response to Trop-2 expressing cells
|
SG10201701424QA
(en)
|
2012-08-23 |
2017-04-27 |
Agensys Inc |
Antibody drug conjugates (adc) that bind to 158p1d7 proteins
|
US10131682B2
(en)
|
2012-11-24 |
2018-11-20 |
Hangzhou Dac Biotech Co., Ltd. |
Hydrophilic linkers and their uses for conjugation of drugs to a cell binding molecules
|
US9492566B2
(en)
|
2012-12-13 |
2016-11-15 |
Immunomedics, Inc. |
Antibody-drug conjugates and uses thereof
|
US10413539B2
(en)
|
2012-12-13 |
2019-09-17 |
Immunomedics, Inc. |
Therapy for metastatic urothelial cancer with the antibody-drug conjugate, sacituzumab govitecan (IMMU-132)
|
US10137196B2
(en)
|
2012-12-13 |
2018-11-27 |
Immunomedics, Inc. |
Dosages of immunoconjugates of antibodies and SN-38 for improved efficacy and decreased toxicity
|
US10744129B2
(en)
|
2012-12-13 |
2020-08-18 |
Immunomedics, Inc. |
Therapy of small-cell lung cancer (SCLC) with a topoisomerase-I inhibiting antibody-drug conjugate (ADC) targeting Trop-2
|
HRP20220399T1
(hr)
|
2012-12-13 |
2022-05-13 |
Immunomedics, Inc. |
Režim doziranja imunokonjugata protutijela i sn-38 za poboljšanu učinkovitost i smanjenu toksičnost
|
US9931417B2
(en)
|
2012-12-13 |
2018-04-03 |
Immunomedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US9107960B2
(en)
|
2012-12-13 |
2015-08-18 |
Immunimedics, Inc. |
Antibody-SN-38 immunoconjugates with a CL2A linker
|
US10206918B2
(en)
|
2012-12-13 |
2019-02-19 |
Immunomedics, Inc. |
Efficacy of anti-HLA-DR antiboddy drug conjugate IMMU-140 (hL243-CL2A-SN-38) in HLA-DR positive cancers
|
US11053316B2
(en)
|
2013-01-14 |
2021-07-06 |
Xencor, Inc. |
Optimized antibody variable regions
|
AU2014205086B2
(en)
|
2013-01-14 |
2019-04-18 |
Xencor, Inc. |
Novel heterodimeric proteins
|
US9605084B2
(en)
|
2013-03-15 |
2017-03-28 |
Xencor, Inc. |
Heterodimeric proteins
|
US10487155B2
(en)
|
2013-01-14 |
2019-11-26 |
Xencor, Inc. |
Heterodimeric proteins
|
US10968276B2
(en)
|
2013-03-12 |
2021-04-06 |
Xencor, Inc. |
Optimized anti-CD3 variable regions
|
US10131710B2
(en)
|
2013-01-14 |
2018-11-20 |
Xencor, Inc. |
Optimized antibody variable regions
|
US9701759B2
(en)
|
2013-01-14 |
2017-07-11 |
Xencor, Inc. |
Heterodimeric proteins
|
EP2945969A1
(de)
|
2013-01-15 |
2015-11-25 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
MX2015010682A
(es)
|
2013-02-22 |
2016-05-31 |
Stemcentrx Inc |
Nuevos conjugados de anticuerpos y usos de los mismos.
|
WO2014159835A1
(en)
|
2013-03-14 |
2014-10-02 |
Genentech, Inc. |
Anti-b7-h4 antibodies and immunoconjugates
|
US9562099B2
(en)
|
2013-03-14 |
2017-02-07 |
Genentech, Inc. |
Anti-B7-H4 antibodies and immunoconjugates
|
US10858417B2
(en)
|
2013-03-15 |
2020-12-08 |
Xencor, Inc. |
Heterodimeric proteins
|
US10519242B2
(en)
|
2013-03-15 |
2019-12-31 |
Xencor, Inc. |
Targeting regulatory T cells with heterodimeric proteins
|
MY174813A
(en)
|
2013-03-15 |
2020-05-16 |
Zymeworks Inc |
Cytotoxic and anti-mitotic compounds, and methods of using the same
|
CN111138543A
(zh)
|
2013-03-15 |
2020-05-12 |
Xencor股份有限公司 |
异二聚体蛋白
|
EP3421495A3
(de)
|
2013-03-15 |
2019-05-15 |
Xencor, Inc. |
Modulation von t-zellen mit bispezifischen antikörpern und fc-fusionen
|
US10106624B2
(en)
|
2013-03-15 |
2018-10-23 |
Xencor, Inc. |
Heterodimeric proteins
|
US11253606B2
(en)
|
2013-07-23 |
2022-02-22 |
Immunomedics, Inc. |
Combining anti-HLA-DR or anti-Trop-2 antibodies with microtubule inhibitors, PARP inhibitors, Bruton kinase inhibitors or phosphoinositide 3-kinase inhibitors significantly improves therapeutic outcome in cancer
|
JP6510518B2
(ja)
|
2013-08-01 |
2019-05-08 |
アジェンシス,インコーポレイテッド |
Cd37タンパク質に結合する抗体薬物結合体(adc)
|
EP3338793A1
(de)
|
2013-08-28 |
2018-06-27 |
AbbVie Stemcentrx LLC |
Neuartige sez6-modulatoren und verfahren zur verwendung
|
EP3892294A1
(de)
|
2013-08-28 |
2021-10-13 |
AbbVie Stemcentrx LLC |
Konjugationsverfahren stellenspezifischer antikörper und zusammensetzungen
|
CN105518027A
(zh)
|
2013-09-17 |
2016-04-20 |
豪夫迈·罗氏有限公司 |
使用抗lgr5抗体的方法
|
MX2016003744A
(es)
|
2013-10-11 |
2016-08-11 |
Us Health |
Anticuerpos tem8 y su uso.
|
PT3055331T
(pt)
|
2013-10-11 |
2021-04-05 |
Oxford Bio Therapeutics Ltd |
Anticorpos conjugados contra ly75 para o tratamento de cancro
|
US11103593B2
(en)
|
2013-10-15 |
2021-08-31 |
Seagen Inc. |
Pegylated drug-linkers for improved ligand-drug conjugate pharmacokinetics
|
WO2015061206A2
(en)
|
2013-10-21 |
2015-04-30 |
North Carolina State University |
Methods and constructs for compound delivery
|
US20160280798A1
(en)
|
2013-11-06 |
2016-09-29 |
The United States Of America, As Represented By The Secretary Department Of Health & Human Service |
Alk antibodies, conjugates, and chimeric antigen receptors, and their use
|
WO2015077605A1
(en)
|
2013-11-25 |
2015-05-28 |
Seattle Genetics, Inc. |
Preparing antibodies from cho cell cultures for conjugation
|
MA39095A1
(fr)
|
2013-12-13 |
2018-08-31 |
Genentech Inc |
Anticorps et immunoconjugués anti-cd33
|
RU2689388C1
(ru)
|
2013-12-16 |
2019-05-28 |
Дженентек, Инк. |
Пептидомиметические соединения и их конъюгаты антител с лекарственными средствами
|
CA2935077C
(en)
|
2013-12-27 |
2022-03-15 |
Geoffrey C. Winters |
Sulfonamide-containing linkage systems for drug conjugates
|
WO2015103549A1
(en)
|
2014-01-03 |
2015-07-09 |
The United States Of America, As Represented By The Secretary Department Of Health And Human Services |
Neutralizing antibodies to hiv-1 env and their use
|
US10548985B2
(en)
|
2014-01-10 |
2020-02-04 |
Birdie Biopharmaceuticals, Inc. |
Compounds and compositions for treating EGFR expressing tumors
|
US9675671B2
(en)
|
2014-01-12 |
2017-06-13 |
Igf Oncology, Llc |
Fusion proteins containing insulin-like growth factor-1 and epidermal growth factor and variants thereof and uses thereof
|
JP2017514143A
(ja)
|
2014-02-21 |
2017-06-01 |
アッヴィ・ステムセントルクス・エル・エル・シー |
メラノーマに使用するための抗dll3抗体および薬物コンジュゲート
|
US10464955B2
(en)
|
2014-02-28 |
2019-11-05 |
Hangzhou Dac Biotech Co., Ltd. |
Charged linkers and their uses for conjugation
|
TW202214691A
(zh)
|
2014-03-21 |
2022-04-16 |
美商艾伯維有限公司 |
抗-egfr抗體及抗體藥物結合物
|
AU2015237200A1
(en)
|
2014-03-27 |
2016-10-06 |
The Brigham And Women's Hospital, Inc. |
Metabolically-activated drug conjugates to overcome resistance in cancer therapy
|
EP3954713A3
(de)
|
2014-03-28 |
2022-03-30 |
Xencor, Inc. |
Bispezifische, an cd38 und cd3 bindende antikörper
|
MX2016015162A
(es)
|
2014-05-22 |
2017-03-03 |
Genentech Inc |
Anticuerpos anti - gpc3 e inmunoconjugados.
|
EP3194449A1
(de)
|
2014-07-24 |
2017-07-26 |
Xencor, Inc. |
Schnelle beseitigung von antigenkomplexen unter verwendung neuartiger antikörper
|
CN112587672A
(zh)
|
2014-09-01 |
2021-04-02 |
博笛生物科技有限公司 |
用于治疗肿瘤的抗-pd-l1结合物
|
EA201790545A1
(ru)
|
2014-09-12 |
2017-07-31 |
Дженентек, Инк. |
Антитела и иммуноконъюгаты против her2
|
EP3191518B1
(de)
|
2014-09-12 |
2020-01-15 |
Genentech, Inc. |
Anti-b7-h4-antikörper und immunkonjugate
|
EP3191134B1
(de)
|
2014-09-12 |
2019-11-20 |
Genentech, Inc. |
Anthracyclindisulfidzwischenprodukte, antikörper-wirkstoff-konjugate und verfahren
|
CA2957354A1
(en)
|
2014-09-12 |
2016-03-17 |
Genentech, Inc. |
Cysteine engineered antibodies and conjugates
|
US9751946B2
(en)
|
2014-09-12 |
2017-09-05 |
Genentech, Inc. |
Anti-CLL-1 antibodies and immunoconjugates
|
DK3194421T3
(da)
|
2014-09-17 |
2022-02-14 |
Zymeworks Inc |
Cytotoksiske og antimitotiske forbindelser samt fremgangsmåder til anvendelse heraf
|
PL3262071T3
(pl)
|
2014-09-23 |
2020-08-10 |
F. Hoffmann-La Roche Ag |
Sposób stosowania immunokoniugatów anty-CD79b
|
EP3786182A1
(de)
|
2014-11-19 |
2021-03-03 |
Axon Neuroscience SE |
Humanisierte tau-antikörper bei alzheimer-krankheit
|
BR112017011166A2
(pt)
|
2014-11-26 |
2018-02-27 |
Xencor, Inc. |
anticorpos heterodiméricos que se ligam a cd3 e cd38
|
US10259887B2
(en)
|
2014-11-26 |
2019-04-16 |
Xencor, Inc. |
Heterodimeric antibodies that bind CD3 and tumor antigens
|
CA2967426A1
(en)
|
2014-11-26 |
2016-06-02 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and tumor antigens
|
WO2016105450A2
(en)
|
2014-12-22 |
2016-06-30 |
Xencor, Inc. |
Trispecific antibodies
|
US10227411B2
(en)
|
2015-03-05 |
2019-03-12 |
Xencor, Inc. |
Modulation of T cells with bispecific antibodies and FC fusions
|
US10472395B2
(en)
|
2015-03-05 |
2019-11-12 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
RU2739617C2
(ru)
|
2015-03-09 |
2020-12-28 |
Эдженсис, Инк. |
Конъюгаты антитело-лекарственное средство (adc), которые связываются с белками flt3
|
CN113876962A
(zh)
|
2015-04-07 |
2022-01-04 |
纪念斯隆-凯特琳癌症中心 |
纳米粒子免疫偶联物
|
EP3286224A4
(de)
|
2015-04-22 |
2018-11-14 |
Immunomedics, Inc. |
Isolierung, detektion, diagnose und/oder charakterisierung von zirkulierenden trop-2-positiven krebszellen
|
EP3091033A1
(de)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3-antikörper und verwendungen davon
|
SG10202108116SA
(en)
|
2015-06-08 |
2021-08-30 |
Debiopharm International S A |
Anti-cd37 immunoconjugate and anti-cd20 antibody combinations
|
AU2016277121C1
(en)
|
2015-06-12 |
2022-07-14 |
Lentigen Technology, Inc. |
Method to treat cancer with engineered T-cells
|
US10195175B2
(en)
|
2015-06-25 |
2019-02-05 |
Immunomedics, Inc. |
Synergistic effect of anti-Trop-2 antibody-drug conjugate in combination therapy for triple-negative breast cancer when used with microtubule inhibitors or PARP inhibitors
|
IL303690A
(en)
|
2015-06-30 |
2023-08-01 |
Seagen Inc |
Anti–NTB–A antibodies and related preparations and methods
|
CN113350518A
(zh)
|
2015-07-12 |
2021-09-07 |
杭州多禧生物科技有限公司 |
与细胞结合分子的共轭偶联的桥连接体
|
US9839687B2
(en)
|
2015-07-15 |
2017-12-12 |
Suzhou M-Conj Biotech Co., Ltd. |
Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule
|
BR112018003147A2
(pt)
|
2015-08-28 |
2018-09-18 |
Debiopharm International S.A. |
anticorpos e testes para detecção de cd37
|
US10799580B2
(en)
|
2015-09-09 |
2020-10-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Expression vector delivery system and use thereof for inducing an immune response
|
CA2997809A1
(en)
|
2015-10-07 |
2017-04-13 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Il-7r-alpha specific antibodies for treating acute lymphoblastic leukemia
|
US10421810B2
(en)
|
2015-10-09 |
2019-09-24 |
Lentigen Technology, Inc. |
Chimeric antigen receptors and methods of use
|
MA43354A
(fr)
|
2015-10-16 |
2018-08-22 |
Genentech Inc |
Conjugués médicamenteux à pont disulfure encombré
|
WO2017066714A1
(en)
|
2015-10-16 |
2017-04-20 |
Compugen Ltd. |
Anti-vsig1 antibodies and drug conjugates
|
EP3387013B1
(de)
|
2015-12-07 |
2022-06-08 |
Xencor, Inc. |
Cd3 und psma bindende heterodimere antikörper
|
CA3011372A1
(en)
|
2016-02-10 |
2017-08-17 |
Immunomedics, Inc. |
Combination of abcg2 inhibitors with sacituzumab govitecan (immu-132) overcomes resistance to sn-38 in trop-2 expressing cancers
|
WO2017147597A1
(en)
|
2016-02-27 |
2017-08-31 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
Peptide vaccines comprising self-assembling polymer nanoparticles
|
LT3423105T
(lt)
|
2016-03-02 |
2021-09-10 |
Eisai R&D Management Co., Ltd. |
Antikūno-vaisto konjugatai eribulino pagrindu ir jų panaudojimo būdai
|
MA45324A
(fr)
|
2016-03-15 |
2019-01-23 |
Seattle Genetics Inc |
Polythérapie utilisant un adc-liv1 et un agent chimiothérapeutique
|
AU2017237186A1
(en)
|
2016-03-25 |
2018-11-01 |
Seagen Inc. |
Process for the preparation of PEGylated drug-linkers and intermediates thereof
|
EP3454864A4
(de)
|
2016-04-21 |
2021-01-13 |
Abbvie Stemcentrx LLC |
Neuartige anti-bmpr1b-antikörper und verfahren zur verwendung
|
WO2017189483A1
(en)
|
2016-04-25 |
2017-11-02 |
The Johns Hopkins University |
Znt8 assays for drug development and pharmaceutical compositions
|
WO2017189279A1
(en)
|
2016-04-27 |
2017-11-02 |
Immunomedics, Inc. |
Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors
|
SI3455261T1
(sl)
|
2016-05-13 |
2023-01-31 |
Bioatla, Inc. |
Protitelesa proti ROR2, fragmenti protitelesa, njihovi imunokonjugati in uporabe le-teh
|
JP7022080B2
(ja)
|
2016-05-27 |
2022-02-17 |
ジェネンテック, インコーポレイテッド |
部位特異的抗体-薬物複合体の特徴付けのための生化学分析的方法
|
WO2017214456A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-cd98 antibodies and antibody drug conjugates
|
EP3468599A2
(de)
|
2016-06-08 |
2019-04-17 |
AbbVie Inc. |
Anti-cd98-antikörper und antikörperwirkstoffkonjugate
|
CA3027103A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
CN109563167A
(zh)
|
2016-06-08 |
2019-04-02 |
艾伯维公司 |
抗b7-h3抗体和抗体药物偶联物
|
WO2017214335A1
(en)
|
2016-06-08 |
2017-12-14 |
Abbvie Inc. |
Anti-b7-h3 antibodies and antibody drug conjugates
|
MX2018015592A
(es)
|
2016-06-14 |
2019-04-24 |
Xencor Inc |
Anticuerpos inhibidores de puntos de control biespecificos.
|
CA3029328A1
(en)
|
2016-06-28 |
2018-01-04 |
Xencor, Inc. |
Heterodimeric antibodies that bind somatostatin receptor 2
|
EP3494139B1
(de)
|
2016-08-05 |
2022-01-12 |
F. Hoffmann-La Roche AG |
Multivalente und multiepitopische anitikörper mit agonistischer wirkung und verfahren zur verwendung
|
MA45945A
(fr)
|
2016-08-09 |
2019-06-19 |
Seattle Genetics Inc |
Conjugués de médicaments avec des lieurs auto-stabilisants, aux propriétés physiochimiques améliorées
|
US10793632B2
(en)
|
2016-08-30 |
2020-10-06 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018045245A1
(en)
|
2016-09-02 |
2018-03-08 |
Sirenas Llc |
Cyclic peptide analogs and conjugates thereof
|
JP7160482B2
(ja)
|
2016-09-02 |
2022-10-25 |
レンティジェン・テクノロジー・インコーポレイテッド |
Duocarを用いてがんを処置するための組成物および方法
|
AU2017342559B2
(en)
|
2016-10-14 |
2022-03-24 |
Xencor, Inc. |
Bispecific heterodimeric fusion proteins containing IL-15/IL-15Ralpha Fc-fusion proteins and PD-1 antibody fragments
|
JP2020510608A
(ja)
|
2016-11-02 |
2020-04-09 |
デビオファーム インターナショナル, エス. アー. |
抗cd37イムノコンジュゲート療法を改善するための方法
|
NZ752394A
(en)
|
2016-11-14 |
2021-07-30 |
Hangzhou Dac Biotech Co Ltd |
Conjugation linkers, cell binding molecule-drug conjugates containing the likers, methods of making and uses such conjugates with the linkers
|
AU2017361887B2
(en)
|
2016-11-21 |
2019-08-15 |
Cureab Gmbh |
Anti-GP73 antibodies and immunoconjugates
|
EP4183798A1
(de)
|
2017-01-09 |
2023-05-24 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-mesothelin-immuntherapie
|
WO2018158398A1
(en)
|
2017-03-02 |
2018-09-07 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to nectin-4 and uses thereof
|
GB201703876D0
(en)
|
2017-03-10 |
2017-04-26 |
Berlin-Chemie Ag |
Pharmaceutical combinations
|
JP7137896B2
(ja)
|
2017-03-24 |
2022-09-15 |
レンティジェン・テクノロジー・インコーポレイテッド |
抗cd33免疫療法によりがんを処置するための組成物および方法
|
US11730822B2
(en)
|
2017-03-24 |
2023-08-22 |
Seagen Inc. |
Process for the preparation of glucuronide drug-linkers and intermediates thereof
|
WO2018183041A1
(en)
|
2017-03-27 |
2018-10-04 |
Immunomedics, Inc. |
Treatment of trop-2 expressing triple negative breast cancer with sacituzumab govitecan and a rad51 inhibitor
|
EP3606964A4
(de)
|
2017-04-03 |
2020-12-09 |
Immunomedics, Inc. |
Subkutane verabreichung von antikörper-arzneimittelkonjugaten zur krebstherapie
|
IL302880A
(en)
|
2017-04-04 |
2023-07-01 |
Avidea Tech Inc |
Peptide-based ingredients, production methods, and their uses for inducing an immune response
|
WO2018187791A1
(en)
|
2017-04-07 |
2018-10-11 |
Juno Therapeutics, Inc |
Engineered cells expressing prostate-specific membrane antigen (psma) or a modified form thereof and related methods
|
US11932694B2
(en)
|
2017-04-19 |
2024-03-19 |
Bluefin Biomedicine, Inc. |
Anti-VTCN1 antibodies and antibody drug conjugates
|
AU2018259856A1
(en)
|
2017-04-28 |
2019-11-14 |
Ajinomoto Co., Inc. |
Compound having substance that has affinity for soluble protein, cleavable moiety, and reactive group, or salt thereof
|
CA3059593A1
(en)
|
2017-05-21 |
2018-11-29 |
Igf Oncology, Llc |
An insulin-like growth factor-chemotherapeputic conjugate for treating myelodysplastic syndrome
|
JP2020529832A
(ja)
|
2017-06-30 |
2020-10-15 |
ゼンコア インコーポレイテッド |
IL−15/IL−15Rαおよび抗原結合ドメインを含む標的化ヘテロダイマーFc融合タンパク質
|
US11892457B2
(en)
|
2017-07-12 |
2024-02-06 |
The Johns Hopkins University |
Proteoliposome-based ZnT8 self-antigen for type 1 diabetes diagnosis
|
AU2018309735A1
(en)
|
2017-07-31 |
2020-02-20 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD19/CD20 immunotherapy
|
TW201919712A
(zh)
|
2017-08-10 |
2019-06-01 |
法商塞勒尼斯醫療控股公司 |
運送子(cargomers)
|
ES2960419T3
(es)
|
2017-09-15 |
2024-03-04 |
Lentigen Tech Inc |
Composiciones y métodos de tratamiento de cáncer con inmunoterapia anti-CD19
|
ES2958849T3
(es)
|
2017-10-16 |
2024-02-15 |
Lentigen Tech Inc |
Composiciones y métodos para tratar el cáncer con inmunoterapia anti-CD22
|
EP3700577A1
(de)
|
2017-10-23 |
2020-09-02 |
Mablink Bioscience |
Ligand-wirkstoff-konjugat mit einem polysarcosin mit spezifischem molekulargewicht
|
US10981992B2
(en)
|
2017-11-08 |
2021-04-20 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
EP3706793A1
(de)
|
2017-11-08 |
2020-09-16 |
Xencor, Inc. |
Bispezifische und monospezifische antikörper unter verwendung von neuartigen anti-pd-1-sequenzen
|
AU2018375375A1
(en)
|
2017-12-01 |
2020-05-28 |
Seagen Inc. |
CD47 antibodies and uses thereof for treating cancer
|
CA3084495A1
(en)
|
2017-12-01 |
2019-06-06 |
Seattle Genetics, Inc. |
Humanized anti-liv1 antibodies for the treatment of breast cancer
|
WO2019125732A1
(en)
|
2017-12-19 |
2019-06-27 |
Xencor, Inc. |
Engineered il-2 fc fusion proteins
|
AU2018388997A1
(en)
|
2017-12-20 |
2020-07-09 |
Lentigen Technology, Inc. |
Compositions and methods for treating HIV/AIDS with immunotherapy
|
WO2019180150A1
(en)
|
2018-03-22 |
2019-09-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for modulating innate lymphoid cell activity, antibody drug conjugates and uses in therapy
|
MA52135A
(fr)
|
2018-03-23 |
2021-01-27 |
Seagen Inc |
Utilisation de conjugués anticorps-médicament comprenant des agents de rupture de tubuline pour traiter une tumeur solide
|
RU2020135052A
(ru)
|
2018-03-28 |
2022-04-29 |
Аксон Ньюросайенс Се |
Способы выявления и лечения болезни альцгеймера на основе антител
|
AU2019247415A1
(en)
|
2018-04-04 |
2020-10-22 |
Xencor, Inc. |
Heterodimeric antibodies that bind fibroblast activation protein
|
CA3097593A1
(en)
|
2018-04-18 |
2019-10-24 |
Xencor, Inc. |
Pd-1 targeted heterodimeric fusion proteins containing il-15/il-15ra fc-fusion proteins and pd-1 antigen binding domains and uses thereof
|
AU2019256529A1
(en)
|
2018-04-18 |
2020-11-26 |
Xencor, Inc. |
TIM-3 targeted heterodimeric fusion proteins containing IL-15/IL-15Ra Fc-fusion proteins and TIM-3 antigen binding domains
|
EP3796943A2
(de)
|
2018-05-22 |
2021-03-31 |
Avidea Technologies, Inc. |
Verbesserte verfahren zur herstellung von impfstoffen auf peptidbasis
|
IL305431A
(en)
|
2018-06-01 |
2023-10-01 |
Eisai R&D Man Co Ltd |
Antibody drug conjugates of splicing modulators and methods of use
|
CN112261954A
(zh)
|
2018-06-14 |
2021-01-22 |
味之素株式会社 |
具有针对抗体的亲和性物质和生物正交性官能团的化合物或其盐
|
GB201809746D0
(en)
|
2018-06-14 |
2018-08-01 |
Berlin Chemie Ag |
Pharmaceutical combinations
|
JP7413999B2
(ja)
|
2018-06-14 |
2024-01-16 |
味の素株式会社 |
抗体に対する親和性物質、切断性部分および反応性基を有する化合物またはその塩
|
WO2020010079A2
(en)
|
2018-07-02 |
2020-01-09 |
Amgen Inc. |
Anti-steap1 antigen-binding protein
|
CA3113058A1
(en)
|
2018-09-20 |
2020-03-26 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-cd123 immunotherapy
|
CN113286607A
(zh)
|
2018-09-26 |
2021-08-20 |
莱蒂恩技术公司 |
用于用抗cd19/cd22免疫治疗来治疗癌症的组合物和方法
|
JP2022503959A
(ja)
|
2018-10-03 |
2022-01-12 |
ゼンコア インコーポレイテッド |
Il-12ヘテロ二量体fc-融合タンパク質
|
WO2020072681A1
(en)
|
2018-10-03 |
2020-04-09 |
Avidea Technologies, Inc. |
Aromatic ring substituted amphiphilic polymers as drug delivery systems
|
CN113227124A
(zh)
|
2018-10-31 |
2021-08-06 |
味之素株式会社 |
具有针对抗体的亲和性物质、切割性部分及反应性基团的化合物或其盐
|
AU2019387377A1
(en)
|
2018-11-30 |
2021-06-17 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD38 immunotherapy
|
JP2022512401A
(ja)
|
2018-12-13 |
2022-02-03 |
エーザイ・アール・アンド・ディー・マネジメント株式会社 |
ハーボキシジエンスプライシング調節薬抗体-薬物コンジュゲート及びその使用方法
|
WO2020154672A1
(en)
*
|
2019-01-25 |
2020-07-30 |
Yale University |
Anticancer drugs and methods of making and using same
|
WO2020163225A1
(en)
|
2019-02-05 |
2020-08-13 |
Seattle Genetics, Inc. |
Anti-cd228 antibodies and antibody-drug conjugates
|
WO2020180726A1
(en)
|
2019-03-01 |
2020-09-10 |
Xencor, Inc. |
Heterodimeric antibodies that bind enpp3 and cd3
|
EP3934668A1
(de)
|
2019-03-06 |
2022-01-12 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit selbstansteuernden chimären antigen-rezeptoren
|
WO2020191342A1
(en)
|
2019-03-20 |
2020-09-24 |
The Regents Of The University Of California |
Claudin-6 antibodies and drug conjugates
|
JP2022529183A
(ja)
|
2019-04-17 |
2022-06-17 |
アヴィディア テクノロジーズ, インコーポレイテッド |
リガンド提示および/または薬物送達のためのスターポリマーを製造する組成物および方法
|
MX2021012961A
(es)
|
2019-04-24 |
2021-11-25 |
Heidelberg Pharma Res Gmbh |
Conjugados de anticuerpo y farmaco de amatoxina y usos de los mismos.
|
WO2020243546A1
(en)
|
2019-05-30 |
2020-12-03 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-bcma immunotherapy
|
TW202112354A
(zh)
|
2019-06-05 |
2021-04-01 |
美商西雅圖遺傳學公司 |
遮蔽抗體調配物
|
US20220306727A1
(en)
|
2019-06-05 |
2022-09-29 |
Seagen Inc. |
Methods of Purifying Masked Antibodies
|
MX2022000174A
(es)
|
2019-07-02 |
2022-05-20 |
Us Health |
Anticuerpos monoclonales que se enlazan a egfrviii y sus usos.
|
US20210030885A1
(en)
|
2019-07-22 |
2021-02-04 |
Seagen Inc. |
Humanized anti-liv1 antibodies for the treatment of cancer
|
CN115151564A
(zh)
|
2019-10-04 |
2022-10-04 |
思进股份有限公司 |
抗pd-l1抗体和抗体-药物缀合物
|
CA3154710A1
(en)
|
2019-10-04 |
2021-04-08 |
TAE Life Sciences |
Antibody compositions comprising fc mutations and site-specific conjugation properties
|
EP3812008A1
(de)
|
2019-10-23 |
2021-04-28 |
Gamamabs Pharma |
Amh-kompetitiver antagonistischer antikörper
|
WO2021116119A1
(en)
|
2019-12-09 |
2021-06-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to her4 and uses thereof
|
US20230090552A1
(en)
|
2020-01-08 |
2023-03-23 |
Synthis Therapeutics, Inc. |
Alk5 inhibitor conjugates and uses thereof
|
WO2021224186A1
(en)
|
2020-05-04 |
2021-11-11 |
Institut Curie |
New pyridine derivatives as radiosensitizers
|
EP4149558A1
(de)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neues verfahren zur behandlung von kutanen t-zell-lymphomen und tfh-abgeleiteten lymphomen
|
WO2021231976A1
(en)
|
2020-05-14 |
2021-11-18 |
Xencor, Inc. |
Heterodimeric antibodies that bind prostate specific membrane antigen (psma) and cd3
|
KR20230020441A
(ko)
|
2020-06-05 |
2023-02-10 |
에자이 알앤드디 매니지먼트 가부시키가이샤 |
항-bcma 항체-약물 컨쥬게이트 및 이용 방법
|
EP4163294A1
(de)
|
2020-06-09 |
2023-04-12 |
Ajinomoto Co., Inc. |
Modifiziertes ferritin und verfahren zur herstellung davon
|
AU2021296423A1
(en)
|
2020-06-22 |
2023-02-02 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with TSLPR-CD19 or TSLPR-CD22 immunotherapy
|
AU2021320739A1
(en)
|
2020-08-04 |
2023-02-23 |
Seagen Inc. |
Anti-CD228 antibodies and antibody-drug conjugates
|
EP3970752A1
(de)
|
2020-09-17 |
2022-03-23 |
Merck Patent GmbH |
Moleküle mit löslichkeitsmarkierung und zugehörige verfahren
|
US20230381112A1
(en)
|
2020-09-22 |
2023-11-30 |
Vaccitech North America, Inc. |
Compositions and Methods of Manufacturing Amphiphilic Block Copolymers that Form Nanoparticles in Situ
|
EP4217395A1
(de)
|
2020-09-28 |
2023-08-02 |
Seagen Inc. |
Humanisierte anti-liv1-antikörper zur behandlung von krebs
|
IL301769A
(en)
|
2020-10-01 |
2023-05-01 |
Abionyx Pharma Sa |
Methods for treating eye diseases by using complexes based on lipid-binding proteins
|
AU2021364709A1
(en)
|
2020-10-19 |
2023-06-01 |
Barinthus Biotherapeutics North America, Inc. |
Star polymer drug conjugates
|
WO2022084325A1
(en)
|
2020-10-20 |
2022-04-28 |
Institut Curie |
Metallic trans-(n-heterocyclic carbene)-amine-platinum complexes and uses thereof for treating cancer
|
EP4240397A1
(de)
|
2020-11-05 |
2023-09-13 |
Lentigen Technology, Inc. |
Zusammensetzungen und verfahren zur behandlung von krebs mit anti-cd19/cd22-immuntherapie
|
AU2022207278A1
(en)
|
2021-01-18 |
2023-08-03 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained therefrom
|
CA3208296A1
(en)
|
2021-01-18 |
2022-07-21 |
Ajinomoto Co., Inc. |
Compound or salt thereof, and antibody obtained by using the same
|
UY39610A
(es)
|
2021-01-20 |
2022-08-31 |
Abbvie Inc |
Conjugados anticuerpo-fármaco anti-egfr
|
EP4305067A1
(de)
|
2021-03-09 |
2024-01-17 |
Xencor, Inc. |
Cd3 und cldn6 bindende heterodimere antikörper
|
WO2022192586A1
(en)
|
2021-03-10 |
2022-09-15 |
Xencor, Inc. |
Heterodimeric antibodies that bind cd3 and gpc3
|
EP4306535A1
(de)
|
2021-03-11 |
2024-01-17 |
Ajinomoto Co., Inc. |
Verbindung oder salz davon und unter verwendung davon erhaltener antikörper
|
WO2022189618A1
(en)
|
2021-03-12 |
2022-09-15 |
Institut Curie |
Nitrogen-containing heterocycles as radiosensitizers
|
EP4310096A1
(de)
|
2021-03-16 |
2024-01-24 |
Ajinomoto Co., Inc. |
Komplex oder salz davon und verfahren zur herstellung davon
|
JP2024512478A
(ja)
|
2021-03-19 |
2024-03-19 |
ハイデルベルク ファルマ リサーチ ゲゼルシャフト ミット ベシュレンクテル ハフツング |
Bリンパ球特異的アマトキシン抗体コンジュゲート
|
JP2024515934A
(ja)
|
2021-03-30 |
2024-04-11 |
レゴケム バイオサイエンシズ, インク. |
ヒトcldn18.2に対する抗体を含む抗体-薬物コンジュゲートおよびその使用
|
TW202304524A
(zh)
|
2021-04-10 |
2023-02-01 |
美商普方生物製藥美國公司 |
Folr1結合劑、其結合物及使用方法
|
AU2022258815A1
(en)
|
2021-04-15 |
2023-10-19 |
Abionyx Pharma Sa |
Use of lipid binding protein-based complexes in organ preservation solutions
|
EP4326768A1
(de)
|
2021-04-23 |
2024-02-28 |
Profoundbio Us Co. |
Anti-cd70-antikörper, konjugate davon und verfahren zur verwendung davon
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
WO2023288236A1
(en)
|
2021-07-14 |
2023-01-19 |
Seagen Inc. |
Antibody masking domains
|
WO2023049825A1
(en)
|
2021-09-24 |
2023-03-30 |
Seagen Inc. |
Improved antibody masking domains
|
AU2022357933A1
(en)
|
2021-09-30 |
2024-04-11 |
Ajinomoto Co., Inc. |
Conjugate of antibody and functional substance or salt thereof, and antibody derivative and compound or salts thereof to be used in producing conjugate or salt thereof
|
WO2023089314A1
(en)
|
2021-11-18 |
2023-05-25 |
Oxford Biotherapeutics Limited |
Pharmaceutical combinations
|
WO2023092099A1
(en)
|
2021-11-19 |
2023-05-25 |
Ardeagen Corporation |
Gpc3 binding agents, conjugates thereof and methods of using the same
|
US20230338424A1
(en)
|
2022-03-02 |
2023-10-26 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Anti-CD123 Immunotherapy
|
US11590169B1
(en)
|
2022-03-02 |
2023-02-28 |
Lentigen Technology, Inc. |
Compositions and methods for treating cancer with anti-CD123 immunotherapy
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
WO2023194797A1
(en)
|
2022-04-06 |
2023-10-12 |
Abionyx Pharma Sa |
Methods for treating eye diseases using lipid binding protein-based complexes
|
WO2023194539A1
(en)
|
2022-04-07 |
2023-10-12 |
Heidelberg Pharma Research Gmbh |
Methods of improving the therapeutic index of amatoxin-antibody conjugates
|
WO2024026107A2
(en)
|
2022-07-28 |
2024-02-01 |
Lentigen Technology, Inc. |
Chimeric antigen receptor therapies for treating solid tumors
|
US20240075142A1
(en)
|
2022-08-26 |
2024-03-07 |
Lentigen Technology, Inc. |
Compositions and Methods for Treating Cancer with Fully Human Anti-CD20/CD19 Immunotherapy
|
WO2024052503A1
(en)
|
2022-09-08 |
2024-03-14 |
Institut National de la Santé et de la Recherche Médicale |
Antibodies having specificity to ltbp2 and uses thereof
|
WO2024064714A2
(en)
|
2022-09-21 |
2024-03-28 |
Seagen Inc. |
Antibodies that bind cd228
|